Letters Revolving door between government and industry

Future jobs of FDA’s haematology-oncology reviewers

BMJ 2016; 354 doi: https://doi.org/10.1136/bmj.i5055 (Published 27 September 2016) Cite this as: BMJ 2016;354:i5055
  1. Jeffrey Bien, internal medicine resident1,
  2. Vinay Prasad, assistant professor of medicine1
  1. 1Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
  1. prasad{at}ohsu.edu

Medical reviewers at the US Food and Drug Administration are vital to effective regulation, interpreting whether a drug’s harm-benefit balance is favourable. When regulators leave government, some work or consult for the industries they regulated.1 2 Although this “revolving door” has been criticised,1 2 it has not been studied. We sought to measure how often it occurs at the FDA.

Using the set of FDA haematology-oncology drug approvals listed on its …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe